Elkik F, Basdevant A, Corvol P
Arch Mal Coeur Vaiss. 1985 Oct;78(11):1737-9.
A long term prospective study of contraceptive vaginal rings (CVR) that deliver estradiol and D-Norgestrel was conducted in 12 hypertensive women. Blood pressure was measured five times by an oscillometric automatic device during two control cycles, at the 1st, 2nd, 4th, 6th and 9th to 12th cycle of CVR use, and again after a one month recovery period. No significant change in blood pressure was noted during CVR usage and this method of contraception appeared safe in hypertensive women. Plasma renin substrate and plasma antithrombin III were non affected by the treatment. These observations are in marked contrast with the dramatic increase and decrease in these proteins that are respectively observed during oral estroprogestative contraception; and confirm the utility of a way of hormone administration that bypass the liver. The significant decrease in sex binding protein, HDL cholesterol, phospholipids and triglycerides that were observed under CVR treatment could be interpreted as reflecting the androgenic potency of D-Norgestrel.
对12名高血压女性进行了一项关于释放雌二醇和炔诺孕酮的避孕阴道环（CVR）的长期前瞻性研究。在两个对照周期内，通过示波自动装置测量血压5次，在使用CVR的第1、2、4、6和第9至12个周期测量血压，并在1个月的恢复期后再次测量。在使用CVR期间未观察到血压有显著变化，这种避孕方法在高血压女性中似乎是安全的。血浆肾素底物和血浆抗凝血酶III不受该治疗影响。这些观察结果与口服雌孕激素避孕药期间分别观察到的这些蛋白质的急剧增加和减少形成鲜明对比；并证实了一种绕过肝脏的激素给药方式的效用。在CVR治疗下观察到的性结合蛋白、高密度脂蛋白胆固醇、磷脂和甘油三酯的显著降低可以解释为反映了炔诺孕酮的雄激素活性。
